Progress in regulation of centromere protein family on malignant biological behavior of hepatocellular carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

HE Kun ^1,2 , GAO Xiaojin ^1,2 , XIE Mengyi ^1,2 ,  LI Jingdong ^1,2

1. Clinical Medical College of North Sichuan Medical College, Nanchong, Sichuan 637000, P. R. China;
2. The First Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College; Institute of Hepatobiliary, Pancreatic and Intestinal Diseases, North Sichuan Medical College, Nanchong, Sichuan 637000, P. R. China;

Corresponding author：

LI Jingdong, Email: lijingdong358@nsmc.edu.cn

Keywords：

centromere protein; hepatocellular carcinoma; biomarker; malignant biological behavior

DOI：

10.7507/1007-9424.202311056

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To understand the clinical value of centromere proteins (CENPs) in hepatocellular carcinoma and their influence on the malignant biological behavior of hepatocellular carcinoma, and to provide theoretical references for related research in this field. Method Domestic and international databases were searched for relevant literatures on the study of CENPs in hepatocellular carcinoma in recent years to be analyzed and reviewed. Results A total of 11 CENPs closely related to hepatocellular carcinoma had been summarized, which were differentially expressed in hepatocellular carcinoma and correlated with prognosis. CENPs might regulate various malignant biological behaviors such as hepatocellular carcinoma proliferation, metastasis, apoptosis, and resistance to radiotherapy and thus participate in the development of hepatocellular carcinoma via multiple mechanisms. The roles and mechanisms of some CENPs in hepatocellular carcinoma remained unclear. Conclusions CENPs play an essential role in the diagnosis, treatment, and prognosis of hepatocellular carcinoma. They are involved in multiple malignant biological behaviors of hepatocellular carcinoma and are expected to be potential therapeutic targets for hepatocellular carcinoma. However, their roles and mechanisms in hepatocellular carcinoma remain to be investigated.

1.	Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin, 2023, 73(1): 17-48.
2.	Kotsari M, Dimopoulou V, Koskinas J, et al. Immune system and hepatocellular carcinoma (HCC): new insights into HCC progression. Int J Mol Sci, 2023, 24(14): 11471. doi: 10.3390/ijms241411471.
3.	Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604.
4.	Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev, 2023, 42(3): 629-652.
5.	Johnson SC, McClelland SE. Watching cancer cells evolve through chromosomal instability. Nature, 2019, 570(7760): 166-167.
6.	Shi YX, Dai PH, Jiang YF, et al. A pan-cancer landscape of centromere proteins in tumorigenesis and anticancer drug sensitivity. Transl Oncol, 2023, 31: 101658. doi: 10.1016/j.tranon.2023.101658.
7.	Liu X, Wang H, Zhao G. Centromere arotein A goes far beyond the centromere in cancers. Mol Cancer Res, 2022, 20(1): 3-10.
8.	Jiang L, Zhao L, Bi J, et al. Glycolysis gene expression profilings screen for prognostic risk signature of hepatocellular carcinoma. Aging (Albany NY), 2019, 11(23): 10861-10882.
9.	Li Y, Zhu Z, Zhang S, et al. ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth. PLoS One, 2011, 6(3): e17794. doi: 10.1371/journal.pone.0017794.
10.	Liu L, Li Y, Zhang S, et al. Hepatitis B virus X protein mutant upregulates CENP-A expression in hepatoma cells. Oncol Rep, 2012, 27(1): 168-173.
11.	石慧娟, 袁博, 孙荣青, 等. 基于TCGA数据库分析CENPA在肝细胞肝癌中的表达及临床意义. 河南医学研究, 2021, 30(13): 2310-2313.
12.	李咏梅, 祝峙, 陈颖, 等. 靶向着丝粒蛋白A的小RNA干扰对肝癌细胞株HepG2细胞生物学行为的影响. 中华病理学杂志, 2008, 37(02): 124-128.
13.	廖婧妤. CENPA通过转录激活并与YY1协同激活CCND1转录的方式促进肝细胞癌增殖. 华中科技大学, 2022.
14.	Zhang S, Zheng Y, Li X, et al. Cellular senescence-related gene signature as a valuable predictor of prognosis in hepatocellular carcinoma. Aging (Albany NY), 2023, 15(8): 3064-3093.
15.	El-Arabey AA, Salama SA, Abd-Allah AR. CENP-E as a target for cancer therapy: Where are we now? Life Sci, 2018, 208: 192-200.
16.	Chung V, Heath EI, Schelman WR, et al. First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemother Pharmacol, 2012, 69(3): 733-741.
17.	Liu Z, Ling K, Wu X, et al. Reduced expression of cenp-e in human hepatocellular carcinoma. J Exp Clin Cancer Res, 2009, 28(1): 156. doi: 10.1186/1756-9966-28-156.
18.	He P, Hu P, Yang C, et al. Reduced expression of CENP-E contributes to the development of hepatocellular carcinoma and is associated with adverse clinical features. Biomed Pharmacother, 2020, 123: 109795. doi: 10.1016/j.biopha.2019.109795.
19.	Yang WX, Gao HW, Cui JB, et al. Development and validation of a coagulation-related genes prognostic model for hepatocellular carcinoma. BMC Bioinformatics, 2023, 24(1): 89. doi: 10.1186/s12859-023-05220-4.
20.	周成杰, 韩哲, 王星月, 等. CENPF在有丝分裂及肿瘤发生中的研究进展. 内蒙古大学学报(自然科学版), 2021, 52(1): 104-112.
21.	Chen J, Lian Y, Zhao B, et al. Deciphering the prognostic and therapeutic significance of cell cycle regulator CENPF: A potential biomarker of prognosis and immune microenvironment for patients with liposarcoma. Int J Mol Sci, 2023, 24(8): 7010. doi: 10.3390/ijms24087010.
22.	Zhang J, Wang Z, Liu Z, et al. CENPF promotes the proliferation of renal cell carcinoma in vitro. Transl Androl Urol, 2023, 12(2): 320-329.
23.	Ji Y, Yin Y, Zhang W. Integrated bioinformatic analysis identifies networks and promising biomarkers for hepatitis B virus-related hepatocellular carcinoma. Int J Genomics, 2020, 2020: 2061024. doi: 10.1155/2020/2061024.
24.	Zhang Y, Tang Y, Guo C, et al. Integrative analysis identifies key mRNA biomarkers for diagnosis, prognosis, and therapeutic targets of HCV-associated hepatocellular carcinoma. Aging (Albany NY), 2021, 13(9): 12865-12895.
25.	Si T, Huang Z, Jiang Y, et al. Expression levels of three key genes CCNB1, CDC20, and CENPF in HCC are associated with antitumor immunity. Front Oncol, 2021, 11: 738841. doi: 10.3389/fonc.2021.738841.
26.	Chen H, Wu F, Xu H, et al. Centromere protein F promotes progression of hepatocellular carcinoma through ERK and cell cycle-associated pathways. Cancer Gene Ther, 2022, 29(7): 1033-1042.
27.	Ho DW, Lam WM, Chan LK, et al. Investigation of functional synergism of CENPF and FOXM1 identifies POLD1 as downstream target in hepatocellular carcinoma. Front Med (Lausanne), 2022, 9: 860395. doi: 10.3389/fmed.2022.860395.
28.	Guo Y, Hu J, Zhao Z, et al. Identification of a prognostic model based on 2-gene signature and analysis of corresponding tumor microenvironment in alcohol-related hepatocellular carcinoma. Front Oncol, 2021, 11: 719355. doi: 10.3389/fonc.2021.719355.
29.	Huang Y, Chen X, Wang L, et al. Centromere protein F ( CENPF) serves as a potential prognostic biomarker and target for human hepatocellular carcinoma. J Cancer, 2021, 12(10): 2933-2951.
30.	李潇瑾, 徐安健, 周东虎, 等. 着丝粒蛋白F在肝癌中的表达和对肝癌细胞生物学行为的影响. 临床和实验医学杂志, 2018, 17(19): 2017-2021.
31.	Li X, Li Y, Xu A, et al. Apoptosis-induced translocation of centromere protein F in its corresponding autoantibody production in hepatocellular carcinoma. Oncoimmunology, 2021, 10(1): 1992104. doi: 10.1080/2162402X.2021.1992104.
32.	李丹, 黄育刚, 汤显斌. 肝细胞肝癌中CENPF的表达及临床意义. 临床与实验病理学杂志, 2021, 37(9): 1115-1118.
33.	Lu G, Shan T, He S, et al. Overexpression of CENP-H as a novel prognostic biomarker for human hepatocellular carcinoma progression and patient survival. Oncol Rep, 2013, 30(5): 2238-2244.
34.	Cong R, Kong F, Ma J, et al. The PVT1/miR-612/CENP-H/CDK1 axis promotes malignant progression of advanced endometrial cancer. Am J Cancer Res, 2021, 11(4): 1480-1502.
35.	Li Q, Huang X, Li QY, et al. CENPH overexpression promotes the progression, cisplatin resistance, and poor prognosis of lung adenocarcinoma via the AKT and ERK/P38 pathways. Am J Cancer Res, 2023, 13(5): 1682-1697.
36.	Yu Z, Ma X, Zhang W, et al. Microarray data mining and preliminary bioinformatics analysis of hepatitis D virus-associated hepatocellular carcinoma. Biomed Res Int, 2021, 2021: 1093702. doi: 10.1155/2021/1093702.
37.	Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci, 2018, 5(12): 181006. doi: 10.1098/rsos.181006.
38.	Lu G, Hou H, Lu X, et al. CENP-H regulates the cell growth of human hepatocellular carcinoma cells through the mitochondrial apoptotic pathway. Oncol Rep, 2017, 37(6): 3484-3492.
39.	Zeng H, Shen Y, Hirachan S, et al. Pan-cancer investigation of CENPK gene: clinical significance and oncogenic immunology. Am J Transl Res, 2021, 13(12): 13336-13355.
40.	Tian H, Wang F, Deng Y, et al. Centromeric protein K (CENPK) promotes gastric cancer proliferation and migration via interacting with XRCC5. Gastric Cancer, 2022, 25(5): 879-895.
41.	Wu S, Cao L, Ke L, et al. Knockdown of CENPK inhibits cell growth and facilitates apoptosis via PTEN-PI3K-AKT signalling pathway in gastric cancer. J Cell Mol Med, 2021, 25(18): 8890-8903.
42.	Wang H, Liu W, Liu L, et al. Overexpression of centromere protein K (CENP-K) gene in hepatocellular carcinoma promote cell proliferation by activating AKT/TP53 signal pathway. Oncotarget, 2017, 8(43): 73994-74005.
43.	Wang J, Li H, Xia C, et al. Downregulation of CENPK suppresses hepatocellular carcinoma malignant progression through regulating YAP1. Onco Targets Ther, 2019, 12: 869-882.
44.	Feng Z, Chen Y, Cai C, et al. Pan-cancer and single-cell analysis reveals CENPL as a cancer prognosis and immune infiltration-related biomarker. Front Immunol, 2022, 13: 916594. doi: 10.3389/fimmu.2022.916594.
45.	Zeng Z, Jiang X, Pan Z, et al. Highly expressed centromere protein L indicates adverse survival and associates with immune infiltration in hepatocellular carcinoma. Aging (Albany NY), 2021, 13(19): 22802-22829.
46.	方坚, 阮梅, 夏磊, 等. 着丝粒蛋白L表达与肝移植术后肝细胞癌复发的关联性研究. 中国临床新医学, 2022, 15(12): 1147-1152.
47.	He K, Xie M, Hong W, et al. CENPL accelerates cell proliferation, cell cycle, apoptosis, and glycolysis via the MEK1/2-ERK1/2 pathway in hepatocellular carcinoma. Int J Biochem Cell Biol, 2024, 166: 106481. doi: 10.1016/j.biocel.2023.106481.
48.	Brickner AG, Evans AM, Mito JK, et al. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood, 2006, 107(9): 3779-3786.
49.	Xiao Y, Najeeb RM, Ma D, et al. Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms. J Exp Clin Cancer Res, 2019, 38(1): 458. doi: 10.1186/s13046-019-1444-0.
50.	Ren H, Wei ZC, Sun YX, et al. ATF2-induced overexpression of lncRNA LINC00882, as a novel therapeutic target, accelerates hepatocellular carcinoma progression via sponging miR-214-3p to upregulate CENPM. Front Oncol, 2021, 11: 714264. doi: 10.3389/fonc.2021.714264.
51.	Duan J, Qian Y, Fu X, et al. TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma. Aging (Albany NY), 2021, 13(4): 5585-5606.
52.	Wu ZH, Yang DL. High CENPM mRNA expression and its prognostic significance in hepatocellular carcinoma: a study based on data mining. Cancer Cell Int, 2020, 20: 406. doi: 10.1186/s12935-020-01499-y.
53.	Yu Z, Wang R, Chen F, et al. Five novel oncogenic signatures could be utilized as AFP-related diagnostic biomarkers for hepatocellular carcinoma based on next-generation sequencing. Dig Dis Sci, 2018, 63(4): 945-957.
54.	Chittori S, Hong J, Saunders H, et al. Structural mechanisms of centromeric nucleosome recognition by the kinetochore protein CENP-N. Science, 2018, 359(6373): 339-343.
55.	Qi CL, Huang ML, Zou Y, et al. The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis. J Exp Clin Cancer Res, 2021, 40(1): 390. doi: 10.1186/s13046-021-02191-3.
56.	周艳琳, 刘俊, 李勇莉, 等. 基于生物信息学分析CENPN在肝癌中的预后价值和作用机制. 中国免疫学杂志, 2022, 38(13): 1590-1596.
57.	Wang Q, Yu X, Zheng Z, et al. Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma. PeerJ, 2021, 9: e11342. doi: 10.7717/peerj.11342.
58.	Cao Y, Xiong J, Li Z, et al. CENPO expression regulates gastric cancer cell proliferation and is associated with poor patient prognosis. Mol Med Rep, 2019, 20(4): 3661-3670.
59.	Shi T, Hu Z, Tian L, et al. Pan-cancer landscape of CENPO and its underlying mechanism in LUAD. Respir Res, 2023, 24(1): 113. doi: 10.1186/s12931-023-02408-3.
60.	He K, Xie M, Li J, et al. CENPO is associated with immune cell infiltration and is a potential diagnostic and prognostic marker for hepatocellular carcinoma. Int J Gen Med, 2022, 15: 7493-7510.
61.	Xu ZW. Gene mining of immune microenvironment in hepatocellular carcinoma. Medicine (Baltimore), 2022, 101(35): e30453. doi: 10.1097/MD.0000000000030453.
62.	Lou Y, Lu J, Zhang Y, et al. The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinoma. Cancer Lett, 2022, 532: 215599. doi: 10.1016/j.canlet.2022.215599.
63.	Deng T, Jiang X, He Z, et al. Centromere protein U (CENPU) promotes gastric cancer cell proliferation and glycolysis by regulating high mobility group box 2 (HMGB2). Bioengineered, 2021, 12(2): 10194-10202.
64.	Yu Y, Chen X, Zhang W, et al. Abnormal expression of centromere protein U is associated with hepatocellular cancer progression. Biomed Res Int, 2021, 2021: 4051192. doi: 10.1155/2021/4051192.
65.	Wang L, Zhou L, Hou J, et al. Three novel circRNAs upregulated in tissue and plasma from hepatocellular carcinoma patients and their regulatory network. Cancer Cell Int, 2021, 21(1): 72. doi: 10.1186/s12935-021-01762-w.
66.	Liu Y, Yao Y, Liao B, et al. A positive feedback loop of CENPU/E2F6/E2F1 facilitates proliferation and metastasis via ubiquitination of E2F6 in hepatocellular carcinoma. Int J Biol Sci, 2022, 18(10): 4071-4087.
67.	Malilas W, Koh SS, Kim S, et al. Cancer upregulated gene 2, a novel oncogene, enhances migration and drug resistance of colon cancer cells via STAT1 activation. Int J Oncol, 2013, 43(4): 1111-1116.
68.	Zhou Y, Chai H, Guo L, et al. Knockdown of CENPW inhibits hepatocellular carcinoma progression by inactivatingE2F signaling. Technol Cancer Res Treat, 2021, 20: 15330338211007253. doi: 10.1177/15330338211007253.
69.	Zhou Z, Zhou Z, Huang Z, et al. Histone-fold centromere protein W (CENP-W) is associated with the biological behavior of hepatocellular carcinoma cells. Bioengineered, 2020, 11(1): 729-742.
70.	Ho CM, Lin KT, Shen R, et al. Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma. Comput Struct Biotechnol J, 2022, 20: 1752-1763.

1. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin, 2023, 73(1): 17-48.
2. Kotsari M, Dimopoulou V, Koskinas J, et al. Immune system and hepatocellular carcinoma (HCC): new insights into HCC progression. Int J Mol Sci, 2023, 24(14): 11471. doi: 10.3390/ijms241411471.
3. Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604.
4. Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev, 2023, 42(3): 629-652.
5. Johnson SC, McClelland SE. Watching cancer cells evolve through chromosomal instability. Nature, 2019, 570(7760): 166-167.
6. Shi YX, Dai PH, Jiang YF, et al. A pan-cancer landscape of centromere proteins in tumorigenesis and anticancer drug sensitivity. Transl Oncol, 2023, 31: 101658. doi: 10.1016/j.tranon.2023.101658.
7. Liu X, Wang H, Zhao G. Centromere arotein A goes far beyond the centromere in cancers. Mol Cancer Res, 2022, 20(1): 3-10.
8. Jiang L, Zhao L, Bi J, et al. Glycolysis gene expression profilings screen for prognostic risk signature of hepatocellular carcinoma. Aging (Albany NY), 2019, 11(23): 10861-10882.
9. Li Y, Zhu Z, Zhang S, et al. ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth. PLoS One, 2011, 6(3): e17794. doi: 10.1371/journal.pone.0017794.
10. Liu L, Li Y, Zhang S, et al. Hepatitis B virus X protein mutant upregulates CENP-A expression in hepatoma cells. Oncol Rep, 2012, 27(1): 168-173.
11. 石慧娟, 袁博, 孙荣青, 等. 基于TCGA数据库分析CENPA在肝细胞肝癌中的表达及临床意义. 河南医学研究, 2021, 30(13): 2310-2313.
12. 李咏梅, 祝峙, 陈颖, 等. 靶向着丝粒蛋白A的小RNA干扰对肝癌细胞株HepG2细胞生物学行为的影响. 中华病理学杂志, 2008, 37(02): 124-128.
13. 廖婧妤. CENPA通过转录激活并与YY1协同激活CCND1转录的方式促进肝细胞癌增殖. 华中科技大学, 2022.
14. Zhang S, Zheng Y, Li X, et al. Cellular senescence-related gene signature as a valuable predictor of prognosis in hepatocellular carcinoma. Aging (Albany NY), 2023, 15(8): 3064-3093.
15. El-Arabey AA, Salama SA, Abd-Allah AR. CENP-E as a target for cancer therapy: Where are we now? Life Sci, 2018, 208: 192-200.
16. Chung V, Heath EI, Schelman WR, et al. First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemother Pharmacol, 2012, 69(3): 733-741.
17. Liu Z, Ling K, Wu X, et al. Reduced expression of cenp-e in human hepatocellular carcinoma. J Exp Clin Cancer Res, 2009, 28(1): 156. doi: 10.1186/1756-9966-28-156.
18. He P, Hu P, Yang C, et al. Reduced expression of CENP-E contributes to the development of hepatocellular carcinoma and is associated with adverse clinical features. Biomed Pharmacother, 2020, 123: 109795. doi: 10.1016/j.biopha.2019.109795.
19. Yang WX, Gao HW, Cui JB, et al. Development and validation of a coagulation-related genes prognostic model for hepatocellular carcinoma. BMC Bioinformatics, 2023, 24(1): 89. doi: 10.1186/s12859-023-05220-4.
20. 周成杰, 韩哲, 王星月, 等. CENPF在有丝分裂及肿瘤发生中的研究进展. 内蒙古大学学报(自然科学版), 2021, 52(1): 104-112.
21. Chen J, Lian Y, Zhao B, et al. Deciphering the prognostic and therapeutic significance of cell cycle regulator CENPF: A potential biomarker of prognosis and immune microenvironment for patients with liposarcoma. Int J Mol Sci, 2023, 24(8): 7010. doi: 10.3390/ijms24087010.
22. Zhang J, Wang Z, Liu Z, et al. CENPF promotes the proliferation of renal cell carcinoma in vitro. Transl Androl Urol, 2023, 12(2): 320-329.
23. Ji Y, Yin Y, Zhang W. Integrated bioinformatic analysis identifies networks and promising biomarkers for hepatitis B virus-related hepatocellular carcinoma. Int J Genomics, 2020, 2020: 2061024. doi: 10.1155/2020/2061024.
24. Zhang Y, Tang Y, Guo C, et al. Integrative analysis identifies key mRNA biomarkers for diagnosis, prognosis, and therapeutic targets of HCV-associated hepatocellular carcinoma. Aging (Albany NY), 2021, 13(9): 12865-12895.
25. Si T, Huang Z, Jiang Y, et al. Expression levels of three key genes CCNB1, CDC20, and CENPF in HCC are associated with antitumor immunity. Front Oncol, 2021, 11: 738841. doi: 10.3389/fonc.2021.738841.
26. Chen H, Wu F, Xu H, et al. Centromere protein F promotes progression of hepatocellular carcinoma through ERK and cell cycle-associated pathways. Cancer Gene Ther, 2022, 29(7): 1033-1042.
27. Ho DW, Lam WM, Chan LK, et al. Investigation of functional synergism of CENPF and FOXM1 identifies POLD1 as downstream target in hepatocellular carcinoma. Front Med (Lausanne), 2022, 9: 860395. doi: 10.3389/fmed.2022.860395.
28. Guo Y, Hu J, Zhao Z, et al. Identification of a prognostic model based on 2-gene signature and analysis of corresponding tumor microenvironment in alcohol-related hepatocellular carcinoma. Front Oncol, 2021, 11: 719355. doi: 10.3389/fonc.2021.719355.
29. Huang Y, Chen X, Wang L, et al. Centromere protein F ( CENPF) serves as a potential prognostic biomarker and target for human hepatocellular carcinoma. J Cancer, 2021, 12(10): 2933-2951.
30. 李潇瑾, 徐安健, 周东虎, 等. 着丝粒蛋白F在肝癌中的表达和对肝癌细胞生物学行为的影响. 临床和实验医学杂志, 2018, 17(19): 2017-2021.
31. Li X, Li Y, Xu A, et al. Apoptosis-induced translocation of centromere protein F in its corresponding autoantibody production in hepatocellular carcinoma. Oncoimmunology, 2021, 10(1): 1992104. doi: 10.1080/2162402X.2021.1992104.
32. 李丹, 黄育刚, 汤显斌. 肝细胞肝癌中CENPF的表达及临床意义. 临床与实验病理学杂志, 2021, 37(9): 1115-1118.
33. Lu G, Shan T, He S, et al. Overexpression of CENP-H as a novel prognostic biomarker for human hepatocellular carcinoma progression and patient survival. Oncol Rep, 2013, 30(5): 2238-2244.
34. Cong R, Kong F, Ma J, et al. The PVT1/miR-612/CENP-H/CDK1 axis promotes malignant progression of advanced endometrial cancer. Am J Cancer Res, 2021, 11(4): 1480-1502.
35. Li Q, Huang X, Li QY, et al. CENPH overexpression promotes the progression, cisplatin resistance, and poor prognosis of lung adenocarcinoma via the AKT and ERK/P38 pathways. Am J Cancer Res, 2023, 13(5): 1682-1697.
36. Yu Z, Ma X, Zhang W, et al. Microarray data mining and preliminary bioinformatics analysis of hepatitis D virus-associated hepatocellular carcinoma. Biomed Res Int, 2021, 2021: 1093702. doi: 10.1155/2021/1093702.
37. Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci, 2018, 5(12): 181006. doi: 10.1098/rsos.181006.
38. Lu G, Hou H, Lu X, et al. CENP-H regulates the cell growth of human hepatocellular carcinoma cells through the mitochondrial apoptotic pathway. Oncol Rep, 2017, 37(6): 3484-3492.
39. Zeng H, Shen Y, Hirachan S, et al. Pan-cancer investigation of CENPK gene: clinical significance and oncogenic immunology. Am J Transl Res, 2021, 13(12): 13336-13355.
40. Tian H, Wang F, Deng Y, et al. Centromeric protein K (CENPK) promotes gastric cancer proliferation and migration via interacting with XRCC5. Gastric Cancer, 2022, 25(5): 879-895.
41. Wu S, Cao L, Ke L, et al. Knockdown of CENPK inhibits cell growth and facilitates apoptosis via PTEN-PI3K-AKT signalling pathway in gastric cancer. J Cell Mol Med, 2021, 25(18): 8890-8903.
42. Wang H, Liu W, Liu L, et al. Overexpression of centromere protein K (CENP-K) gene in hepatocellular carcinoma promote cell proliferation by activating AKT/TP53 signal pathway. Oncotarget, 2017, 8(43): 73994-74005.
43. Wang J, Li H, Xia C, et al. Downregulation of CENPK suppresses hepatocellular carcinoma malignant progression through regulating YAP1. Onco Targets Ther, 2019, 12: 869-882.
44. Feng Z, Chen Y, Cai C, et al. Pan-cancer and single-cell analysis reveals CENPL as a cancer prognosis and immune infiltration-related biomarker. Front Immunol, 2022, 13: 916594. doi: 10.3389/fimmu.2022.916594.
45. Zeng Z, Jiang X, Pan Z, et al. Highly expressed centromere protein L indicates adverse survival and associates with immune infiltration in hepatocellular carcinoma. Aging (Albany NY), 2021, 13(19): 22802-22829.
46. 方坚, 阮梅, 夏磊, 等. 着丝粒蛋白L表达与肝移植术后肝细胞癌复发的关联性研究. 中国临床新医学, 2022, 15(12): 1147-1152.
47. He K, Xie M, Hong W, et al. CENPL accelerates cell proliferation, cell cycle, apoptosis, and glycolysis via the MEK1/2-ERK1/2 pathway in hepatocellular carcinoma. Int J Biochem Cell Biol, 2024, 166: 106481. doi: 10.1016/j.biocel.2023.106481.
48. Brickner AG, Evans AM, Mito JK, et al. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood, 2006, 107(9): 3779-3786.
49. Xiao Y, Najeeb RM, Ma D, et al. Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms. J Exp Clin Cancer Res, 2019, 38(1): 458. doi: 10.1186/s13046-019-1444-0.
50. Ren H, Wei ZC, Sun YX, et al. ATF2-induced overexpression of lncRNA LINC00882, as a novel therapeutic target, accelerates hepatocellular carcinoma progression via sponging miR-214-3p to upregulate CENPM. Front Oncol, 2021, 11: 714264. doi: 10.3389/fonc.2021.714264.
51. Duan J, Qian Y, Fu X, et al. TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma. Aging (Albany NY), 2021, 13(4): 5585-5606.
52. Wu ZH, Yang DL. High CENPM mRNA expression and its prognostic significance in hepatocellular carcinoma: a study based on data mining. Cancer Cell Int, 2020, 20: 406. doi: 10.1186/s12935-020-01499-y.
53. Yu Z, Wang R, Chen F, et al. Five novel oncogenic signatures could be utilized as AFP-related diagnostic biomarkers for hepatocellular carcinoma based on next-generation sequencing. Dig Dis Sci, 2018, 63(4): 945-957.
54. Chittori S, Hong J, Saunders H, et al. Structural mechanisms of centromeric nucleosome recognition by the kinetochore protein CENP-N. Science, 2018, 359(6373): 339-343.
55. Qi CL, Huang ML, Zou Y, et al. The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis. J Exp Clin Cancer Res, 2021, 40(1): 390. doi: 10.1186/s13046-021-02191-3.
56. 周艳琳, 刘俊, 李勇莉, 等. 基于生物信息学分析CENPN在肝癌中的预后价值和作用机制. 中国免疫学杂志, 2022, 38(13): 1590-1596.
57. Wang Q, Yu X, Zheng Z, et al. Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma. PeerJ, 2021, 9: e11342. doi: 10.7717/peerj.11342.
58. Cao Y, Xiong J, Li Z, et al. CENPO expression regulates gastric cancer cell proliferation and is associated with poor patient prognosis. Mol Med Rep, 2019, 20(4): 3661-3670.
59. Shi T, Hu Z, Tian L, et al. Pan-cancer landscape of CENPO and its underlying mechanism in LUAD. Respir Res, 2023, 24(1): 113. doi: 10.1186/s12931-023-02408-3.
60. He K, Xie M, Li J, et al. CENPO is associated with immune cell infiltration and is a potential diagnostic and prognostic marker for hepatocellular carcinoma. Int J Gen Med, 2022, 15: 7493-7510.
61. Xu ZW. Gene mining of immune microenvironment in hepatocellular carcinoma. Medicine (Baltimore), 2022, 101(35): e30453. doi: 10.1097/MD.0000000000030453.
62. Lou Y, Lu J, Zhang Y, et al. The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinoma. Cancer Lett, 2022, 532: 215599. doi: 10.1016/j.canlet.2022.215599.
63. Deng T, Jiang X, He Z, et al. Centromere protein U (CENPU) promotes gastric cancer cell proliferation and glycolysis by regulating high mobility group box 2 (HMGB2). Bioengineered, 2021, 12(2): 10194-10202.
64. Yu Y, Chen X, Zhang W, et al. Abnormal expression of centromere protein U is associated with hepatocellular cancer progression. Biomed Res Int, 2021, 2021: 4051192. doi: 10.1155/2021/4051192.
65. Wang L, Zhou L, Hou J, et al. Three novel circRNAs upregulated in tissue and plasma from hepatocellular carcinoma patients and their regulatory network. Cancer Cell Int, 2021, 21(1): 72. doi: 10.1186/s12935-021-01762-w.
66. Liu Y, Yao Y, Liao B, et al. A positive feedback loop of CENPU/E2F6/E2F1 facilitates proliferation and metastasis via ubiquitination of E2F6 in hepatocellular carcinoma. Int J Biol Sci, 2022, 18(10): 4071-4087.
67. Malilas W, Koh SS, Kim S, et al. Cancer upregulated gene 2, a novel oncogene, enhances migration and drug resistance of colon cancer cells via STAT1 activation. Int J Oncol, 2013, 43(4): 1111-1116.
68. Zhou Y, Chai H, Guo L, et al. Knockdown of CENPW inhibits hepatocellular carcinoma progression by inactivatingE2F signaling. Technol Cancer Res Treat, 2021, 20: 15330338211007253. doi: 10.1177/15330338211007253.
69. Zhou Z, Zhou Z, Huang Z, et al. Histone-fold centromere protein W (CENP-W) is associated with the biological behavior of hepatocellular carcinoma cells. Bioengineered, 2020, 11(1): 729-742.
70. Ho CM, Lin KT, Shen R, et al. Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma. Comput Struct Biotechnol J, 2022, 20: 1752-1763.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Latest ArticlesProgress in regulation of centromere protein family on malignant biological behavior of hepatocellular carcinoma

Abstract Full text Figures/Tables Video References Cited by

Format

Content